Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply

John Marquart¹, Emerson Y Chen², Vinay Prasad^{2

3

4}

Affiliations

¹ Oregon Health & Science University School of Medicine, Portland.
² Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland.
³ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland.
⁴ Center for Health Care Ethics, Oregon Health & Science University, Portland.

Comment

John Marquart et al. JAMA Oncol. 2018.

. 2018 Dec 1;4(12):1790.

doi: 10.1001/jamaoncol.2018.5111.

John Marquart¹, Emerson Y Chen², Vinay Prasad^{2

3

4}

¹ Oregon Health & Science University School of Medicine, Portland.
² Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland.
³ Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland.
⁴ Center for Health Care Ethics, Oregon Health & Science University, Portland.

No abstract available

Comment on

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J, Chen EY, Prasad V. Marquart J, et al. JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660. JAMA Oncol. 2018. PMID: 29710180 Free PMC article.
Moving Precision Oncology Forward Amid Myths and Misconceptions.
Janku F, Hess KR, Yap TA. Janku F, et al. JAMA Oncol. 2018 Dec 1;4(12):1788-1789. doi: 10.1001/jamaoncol.2018.5064. JAMA Oncol. 2018. PMID: 30419079 No abstract available.
Moving Precision Oncology Forward Amid Myths and Misconceptions.
Abderrahman B, Jordan VC. Abderrahman B, et al. JAMA Oncol. 2018 Dec 1;4(12):1789-1790. doi: 10.1001/jamaoncol.2018.5067. JAMA Oncol. 2018. PMID: 30419081 No abstract available.